[PDF] Top 20 Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
Has 10000 "Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma" found on our website. Below are the top 20 most common "Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma".
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
... further study is necessary to evaluate this phenomenon. In addition, the 2007 recommendations for staging and assessment of treatment response in patients with and without HL were recently updated, providing new ... See full document
10
Erratum: GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
... of Hodgkin lymphoma by introducing new chemotherapy regimens and combining radiotherapy and chemotherapy has significantly evolved in recent years and failure in treatment is seen only in 10 to 20% of ...of ... See full document
5
Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
... The median number of brentuximab vedotin cycles was five (range 1–18). The response and survival outcomes are summarized in Table 2. Of the 22 patients in the study, one patient (4.5%) was not evaluable for ... See full document
6
<p>The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma</p>
... 7 Phase I and II studies of the chimeric anti-CD30 mAb, SGN-30, demon- strated tolerability, but lacked clinical ...63 relapsed/ refractory patients, however, the median duration of response was only ... See full document
9
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
... primary refractory and relapsed classical Hodgkin lymphoma remains challenging, with disappointing results overall and only a minority of patients enjoying a long- term ... See full document
9
Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience
... present study, 24 patients (92%) with NHL had aggressive lymphomas, in- cluding diffuse large B-cell lymphoma (DLBCL) in 15 ...a phase I/II trial Evens et ...for relapsed/ /refractory ... See full document
7
Preliminary Economic Evaluation of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: An "Early Look" Model Based on Phase II Results
... are selected from Ontario cancer registry and linked to CIHI Discharge Abstract Database (CIHI-DAD), Ontario Health Insurance Plan (OHIP) and Ontario Drug Benefit (ODB) databases to estimate healthcare utilization, cost ... See full document
108
Impact of obinutuzumab alone and in combination for follicular lymphoma
... The Phase II of the GAUSS trial did not produce encour- aging ...This study compared obinutuzumab with rituximab in a larger group of 175 patients with relapsed iNHLs (149 with FL) who required ... See full document
11
Targeted therapy in lymphoma
... a phase II multicenter study in patients with relapsed/refractory aggressive NHL ...low-grade lymphoma [47]. Overall response rates were 35% (4 uCR/2 CR/11 PR) for all 49 ... See full document
10
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
... The safety profiles for PI3K inhibitors warrant careful scrutiny following the recent safety concerns for the oral agent idelalisib [5–7]. Hyperglycemia and hypertension were the most common TEAEs seen with copanlisib, ... See full document
36
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy
... in classical Hodgkin lymphoma (cHL) induce a chronic inflammatory tu- moral microenvironment and heavily overexpresses both PD-L1 and PD-L2 [2, ...[9]. Phase I/II clinical trials of ... See full document
5
Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
... single-arm, Phase II clinical trial, patients were eligible for enrollment after failing at least one prior ...primary study objective was to assess the safety and efficacy of single-agent belinostat in ... See full document
6
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
... The study further divided the other patients into expan- sion cohorts including solid tumors (25 patients), NHL (9 patients) and diabetics (6 ...cohort phase, all patients received the MTD of ... See full document
11
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
... Another Phase II study evaluated the efficacy and safety of brentuximab vedotin in relapsed/refractory CD30 + non- Hodgkin’s lymphomas ...T-cell lymphoma (AITL; n = 13) and PTCL not ... See full document
5
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
... this study experienced periph- eral motor neuropathy of any grade, while 1% had grade 3 ...grade 2, and 38 weeks for grade 3 peripheral ...grade 2–3 symptoms after the drug has been held to allow the ... See full document
7
GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study.
... of Hodgkin lymphoma by introducing new chemotherapy regimens and combining radiotherapy and chemotherapy has significantly evolved in recent years and failure in treatment is seen only in 10 to 20% of ...of ... See full document
5
The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
... this study, 20 were newly diagnosed in stage I/II, 28 newly diagnosed in stage III/IV, 9 had relapsed, and 23 were refractory to the first-line ... See full document
9
Original Article Classical Hodgkin lymphoma with necrotic granuloma-like morphological features
... this study represented a previ- ously unrecognized morphological variant of ...B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and ... See full document
10
The diagnosis and management of NK/T-cell lymphomas
... (NK)/T-cell lymphoma is an aggressive malignancy of putative NK-cell origin, with a minority deriving from the T-cell ...NK/T-cell lymphoma, nasal type; and aggressive NK-cell leukaemia. Lymphoma ... See full document
13
Rapidly Progressing Refractory Hodgkin Lymphoma: A Case Report and a Possible Explanation
... antibiotics and antifungal agents (meropenem + moxi- floxacin and fluconazole and then amphotericin B), fever persisted as a symptom of progressing HL. Therefore 18 FDG- PET/CT ( 18 fluoro-deoxy-glucose-positron emission ... See full document
5
Related subjects